Lexeo Therapeutics (LXEO) Interest Coverage Ratio (2022 - 2026)
Lexeo Therapeutics recorded quarterly Interest Coverage Ratio of 1313.71 in Q1 2026, down 13.66% quarter-over-quarter from 1155.8 in Q4 2025, and down 8.81% year-over-year from 1440.65 in Q1 2025.
Lexeo Therapeutics' Interest Coverage Ratio history runs 5 years deep, the most recent figure standing at 1313.71 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 8.81% year-over-year to 1313.71; the TTM figure through Mar 2026 stood at 1164.11 (down 377.81% YoY), while the FY2025 annual figure was 1150.07, down 662.23% from the prior year.
- Interest Coverage Ratio came in at 1313.71 for Q1 2026 at Lexeo Therapeutics, down from 1155.8 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1923.77 in Q4 2024 to a low of 1313.71 in Q1 2026.
- A 5-year average of 559.42 and a median of 629.49 in 2024 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio soared 742.37% in 2024 and slumped 160.08% in 2025, its largest moves.
- Lexeo Therapeutics' Interest Coverage Ratio stood at 281.43 in 2022, then retreated by 6.42% to 299.48 in 2023, then soared by 742.37% to 1923.77 in 2024, then plunged by 160.08% to 1155.8 in 2025, then dropped by 13.66% to 1313.71 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1313.71, 1155.8, and 984.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | -1,313.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,313.71 |
| Dec 31, 2025 | -1,155.80 |
| Sep 30, 2025 | -984.00 |
| Jun 30, 2025 | -1,227.52 |
| Mar 31, 2025 | -1,207.32 |
| Dec 31, 2024 | 1,923.77 |
| Sep 30, 2024 | -901.23 |
| Jun 30, 2024 | -672.86 |
| Mar 31, 2024 | -629.49 |
| Dec 31, 2023 | -299.48 |
| Sep 30, 2023 | -389.87 |
| Jun 30, 2023 | -263.68 |
| Mar 31, 2023 | -385.80 |
| Dec 31, 2022 | -281.43 |
| Sep 30, 2022 | -602.83 |